Aflibercept in Recurrent or Persistent CNV

Launched by MEDICAL UNIVERSITY OF VIENNA · Jan 27, 2016

Keywords

ClinConnect Summary

This clinical trial is studying the effects of a medication called aflibercept in patients who have certain eye conditions, specifically recurrent or persistent neovascular age-related macular degeneration (nAMD) and diabetic retinopathy. The trial is looking at whether switching from another treatment called ranibizumab to aflibercept can improve vision in patients who have been receiving ranibizumab for up to a year. The study will include 20 adults aged 50 and older who have a specific level of vision in their study eye and are willing to attend regular check-ups.

Participants in this trial can expect to have monthly appointments for a year, during which their vision and eye health will be closely monitored using various tests. These tests will help the researchers understand how well aflibercept works compared to the previous treatment. It's important to note that certain eye conditions or recent surgeries may prevent some people from joining the study. If you're interested or think you might qualify, discussing this with your doctor is a great next step.

Gender

ALL

Eligibility criteria

• Inclusion Criteria:
• • Adults ≥ 50 years
• • Patients who have been treated with ranibizumab due to wet age-related macular degeneration for up to one year
• • BCVA \>= 20/400 in the study eye using ETDRS
• • Willingness and ability to comply with regular visits
• • Signed informed consent
• Exclusion Criteria:
• • Any surgical treatment of the eye within 3 months prior to baseline in the study eye
• • History of uncontrolled glaucoma in the study eye (defined as intraocular pressure ≥ 25 mmHg despite treatment with anti-glaucoma mediation)
• • Aphakia or absence of the posterior capsule (excluding YAG-capsulotomy) in the study eye
• • Retinal pigment epithelial tear involving the macula in the study eye